Abstract:With the integration of the global pharmaceutical economy and the gradual transformation of the healthcare insurance system in China, the legislative framework for a comprehensive regulatory system monitoring the whole process including drug development, manufacture, distribution and use has been established by the China Food and Drug Administration (CFDA) to ensure the safety and effectiveness of medication use. China has established a relatively comprehensive pharmacovigilance system covering regulation, organisation and technology from 1989 to 2014. As of 2013, one national centre, 34 provincial centres and more than 400 municipal centres for adverse drug reaction (ADR) monitoring were included in the four-level pharmacovigilance network (national, provincial, municipal and county) with more than 200,000 grassroot organisation users. The China Adverse Drug Reaction Monitoring System (CADRMS) is an online spontaneous reporting system which connects the four-level pharmacovigilance network. By 2013, CADRMS had received over 6.6 million ADR case reports. After integrating and analysing pharmacovigilance data, the National Centre for ADR Monitoring (NCADRM) publishes medication safety information by releasing ADR bulletins, National ADR Annual Reports and International Pharmacovigilance Newsletters. The NCADRM also routinely provides CADRMS data feedback to manufacturers. The CFDA implemented risk management through several approaches, including arranging ‘manufacturer communication meetings’, modification of medication package inserts, and restriction, suspension or withdrawal of marketing authorisations. Seamless information exchange with overseas regulatory authorities and organisations remains an area for improvement. Further development of the China pharmacovigilance system in terms of signal generation, post-marketing pharmacoepidemiology research and education is also needed.

America's Emergency Precautions and Response Mechanism of Drug Safety

Analysis of emergency Drug Approval System in China and the United States under Public Health emergencies and its enlightenment to China

The Enl Ightment of FDA’s Drug Safety Risk Management Final Guidelines to Drug Safety Risk Management in China

Present situation of drug safety early warning in China and the solution

A Systematic Review and Qualitative Analysis or the Definition and Scope of Drug Safety in China

Research on the Safety Monitoring Effects of Pediatric Drug Data Protection Regime in the US

Chinese Drug Sefety Risk and Crisis Control,Achievement Problems and Solutions

The US FDA drug safety information disclosure and its implication

Study on Drug Electronic Supervision System of California in USA

Pharmacovigilance in China: A review

Understanding on the Problems of Drug Safety

Elements’ Important Ranking of China Drug Safety Management System: Applying the Non-Structural Fuzzy Group Decision Method

Pharmacovigilance in China: Current Situation, Successes and Challenges

Pharmacovigilance in China: Evolution and future challenges.

Analysis of the Drug Safety from the Perspective of Quality Standard

Development Trends of the Post-Marketing Drug Safety Surveillance Systems in EU and US

Data Analysis and Comparative Study on Drug Recall in China And America

Discussions on the standardized safety evaluation of new drugs in phase I clinical trials

Drug Recall System under the Circumstances of New Healthcare Reform

The Regulation of Drug Safety:Based on the Theory of Interest Groups

Problems and Advices of Medicine Emergency Response System for Unexpected Disaster in China